Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

ecancermedicalscience

Submit article
Articles
Editorials
Special issues
Author interviews
https://doi.org/10.3332/ecancer.2008.121
Abstract | Full Article | PDF

Short Communication

Azacitidine prolongs overall survival and reduces infections and hospitalisations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update

10 Dec 2008
P Fenaux, GJ Mufti, E Hellström-Lindberg, V Santini, N Gattermann, G Sanz, AF List, SD Gore, JF Seymour, J Backstrom, L Zimmerman, D McKenzie, CL Beach, LB Silverman

Azacitidine (AZA), as demonstrated in the phase III trial (AZA-001), is the first MDS treatment to significantly prolong overall survival (OS) in higher risk MDS pts ((2007) Blood 110 817). Approximately, one-third of the patients (pts) enrolled in AZA-001 were FAB RAEB-T (¡Ý20¨C30% blasts) and now meet the WHO criteria for acute myeloid leukaemia (AML) ((1999) Blood 17 3835). Considering the poor prognosis (median survival <1 year) and the poor response to chemotherapy in these pts, this sub-group analysis evaluated the effects of AZA versus conventional care regimens (CCR) on OS and on response rates in pts with WHO AML.

Related Articles

2100-establishment-of-the-first-bone-marrow-transplant-program-in-francophone-sub-saharan-africa-clinical-case-and-future-perspectives
Elhadji Daouda Nianga, Seynabou Fall, Sokhna Aissatou Toure, Marieme Lolita Camara, Modou Moustapha Ciss, Adjaratou Tiane Niang, Khadim Sarr, Amy Thiam, Fatou Samba Diago Ndiaye
2097-age-and-sex-based-differences-in-therapy-preferences-among-patients-with-cancer-evidence-from-a-novel-therapy-preference-scale
Prajwal Dhakal, Christopher S Wichman, Shailesh Simkhada, Bunny J Pozehl, Radowan Elnair, Amulya Yellala, Kalika Mahato, Vijaya Raj Bhatt
2098-prospective-evaluation-of-locoregional-control-in-oral-cavity-squamous-cell-carcinoma-with-lower-or-mid-infratemporal-fossa-involvement-treated-with-surgery-and-adjuvant-concurrent-chemoradiotherapy
Prasoon Mishra, Rahat Hadi, Ajeet Kumar Gandhi, Madhup Rastogi, Rohini Khurana, Ashish Singhal, Surendra Prasad Mishra, Anoop Srivastava, Avinav Bharati, Ashish Chandra Agarwal, Avinash Poojari, Vachaspati Kumar Mishra, Raunaq Puri, Akanksha Manral, Vikas Gupta, Bhoopendra Pratap Vishwaranjan, Saumyta Mishra
2096-disparities-in-oral-cancer-screening-among-indian-women-aged-30-49-insights-from-a-national-survey
Navjot Kaur, Pritam Halder, Yuvaraj Krishnamoorthy, Gursimer Jeet, Garima Bhatt, Sathish Rajaa, Priyanka Sudhir, Rohit Sharma, Sarthak Tandon, Manish Gupta
2092-clinical-therapeutic-and-prognostic-characteristics-of-de-novo-metastatic-breast-cancer-in-cameroon
Berthe Sabine Esson Mapoko, Etienne Atenguena, Abdel Nasser Nsangou Moun, Esther Dina Bell, Lionel Tabola, Dominique Anaba, Anne Sango, Rachel Tayou
2093-cancer-profile-among-medical-evacuees-from-so-tome-and-principe-a-descriptive-study-2019-2025
Liudmila Castelo David, Teresa Mota Garcia, Isaulina Barreto, Esperança Carvalho, Laurinda Barreto, Clara Aleydis, Laurinda Coelho, Lúcio Lara Santos

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation